- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03483467
Omnigen DFU Pilot Study
Pilot Study - Effectiveness of Omnigen in Addition to Standard Treatment in Treating Diabetic Foot Ulcers (DFU)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pilot study is designed as a multi-centre prospective, patient and observer blind, randomised controlled trial, recruiting patients from two clinical centres across the East Midlands; Derby Teaching Hospitals NHS Foundation Trust (DHFT) and Nottingham University Hospitals NHS Trust (NUH).
Eligible patients will be approached within diabetic foot clinics by their usual clinical carers to determine whether they are interested in participating in the study. They will be provided with written information about the study and the researcher will explain the study verbally to them and address any questions and concerns the patient may have. Patents will be given at least 24 hours to consider taking part in the trial before signing a consent form.
After informed consent has been given, baseline information will be collected. This will include demographic information, medical history and concomitant medication. eGFR and HbA1c will also be collected if not done within previous 3 months as part of standard care. The baseline wound status, assessment of ulcer infection according to Infectious Diseases Society of America (IDSA) criteria, peripheral pulses, neuropathy and ankle brachial pressure index will also be taken.
Participants will then be randomised to receive either standard of care or Omnigen graft with standard of care. Staff administering the Omnigen product will be aware of which treatment the participant is receiving however the participant and the research staff conducting the healing assessments will be blinded to their treatment allocation. Therefore the participant and the assessors will be blinded to the treatment given in order to minimize any bias in the collection of healing outcome data. For those randomized into the control arm, 'Dummy Packaging' will be used to ensure the blind is maintained.
Patients will be seen two weekly from their baseline visit until healing for up to 12 weeks and at 2 weeks post healing in those that heal. If a participant's foot ulcer heals before the final 12 weeks visit, they will attend a healing confirmation visit two weeks post the original heal date, however will not be required to attend any further fortnightly visits until the final blinded assessment visit at week 12 . If the participant's foot ulcer has not healed at 12 weeks then a blinded assessment should still be conducted at this time point.
Data is collected using the Dacima Clinical Suite Electronic Data Capture (EDC) software (Dacima Software Inc.)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Derby, United Kingdom
- University Hospitals Derby and Burton, Royal Derby Hospital
-
Nottingham, United Kingdom
- University of Nottingham Teachig Hospitals, City Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with diabetes (according to WHO criteria) aged 18 years or over
- At least one full thickness ulcer below the malleolus of either foot, present for 4 weeks or more.
- At least one palpable pulse on the foot of the index limb or an ABPI >0.9
- Minimum ulcer diameter of 5 mm
- Maximum ulcer diameter of 20 mm.
- Able to attend clinic on a fortnightly basis
Exclusion Criteria:
- eGFR <20
- HbA1c >108
- Planned revascularisation during the course of the study or within the 4 weeks preceding the start of the study
- An ulcer of aetiology other than diabetes
- Depth of ulcer to bone, suspected or confirmed osteomyelitis
- Severe infection of the index ulcer
- Active Charcot of the foot of the index ulcer
- The need for negative pressure wound therapy
- On treatment with systemic steroids at a dose > equivalent of 5mg prednisolone for more than 5 days and/or systemic cytotoxic agents
- Unwilling or unable to attend all trial visits.
- Unwilling or unable to give written informed consent.
- Lacks the mental capacity to give consent
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, may influence the result of the trial or the participant's ability to participate in the trial
- Participants who have participated in another research trial involving a wound healing product within the past 12 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Application of Omnigen
|
For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
|
PLACEBO_COMPARATOR: 2
Dummy Omnigen Packaging
|
For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome is wound healing (defined as full epithelialisation without drainage maintained for 2 weeks) within 12 weeks of starting study treatment.
Time Frame: 12 weeks
|
To assess the whether higher proportion of wounds heal at 12 weeks in the investigational arm to the control arm - assessed by confirmation of healing at 12 week visit.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall reduction in wound size (surface area, assessed by acetate tracing)
Time Frame: 12 weeks
|
To assess the whether higher proportion of wounds reduce in size at 12 weeks in the investigational arm to the control arm - assessed by comparing acetate tracing in each arm.
|
12 weeks
|
Time to healing (weeks) for those that heal within 12 weeks,
Time Frame: 12 weeks
|
To assess the whether higher proportion of wounds heal at 12 weeks in the investigational arm to the control arm - assessed by proportion of confirmation of heeling visits conducted at 12 weeks within each arm.
|
12 weeks
|
Proportion of wounds healed within 6 weeks
Time Frame: 6 weeks
|
To assess the whether higher proportion of wounds heal at 6 weeks in the investigational arm to the control arm - assessed by proportion of confirmation of heeling visits conducted at 6 weeks within each arm.
|
6 weeks
|
Adverse events (safety) including major and minor amputations and hospitalisation
Time Frame: 12 weeks
|
To assess the safety of the intervention of Omnigen in comparison to standard of care.
Review of SAEARs.
|
12 weeks
|
Incidence of secondary infection
Time Frame: 12 weeks
|
To assess the safety of the intervention of Omnigen in comparison to standard of care.
Review of SAEARs.
|
12 weeks
|
Feasibility of recruitment
Time Frame: 12 weeks
|
To assess the feasibility of the study in regards to recruitment for a future full RCT.
Recruitment rate, reasons for patients not randomising and reasons for investigators not randomising.
Screening logs/protocol deviations.
|
12 weeks
|
Pain in the area of the ulcer as assessed by patient completed VAS
Time Frame: 12 weeks
|
To assess pain of ulcer through completion of VAS at every fortnightly visit to identify if pain reduces at a higher rate on the interventional arm than the control arm.
|
12 weeks
|
Effectiveness of participant blind
Time Frame: 12 weeks
|
To assess whether the blinding to arm allocation has been successful with the use of dummy packaging or whether the participants are able to identify which treatment they have received.
This will be done by completion of a participant questionnaire at the end of the study.
|
12 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHRD/2017/042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Omnigen
-
Farwaniya HospitalCompleted
-
Aston UniversityNuVisionCompleted